Coronary heart disease in women: Hormone replacement therapy
- 34 Downloads
For both primary and secondary prevention of coronary heart disease (CHD), it is prudent to use strategies that are of proven benefit and that do not harm patients. In all women, these strategies include lifestyle approaches such as smoking avoidance, proper nutrition, and regular exercise. Lipid-lowering and blood pressure control with pharmacotherapy are indicated in women who do not meet target lipid or blood pressure levels with lifestyle interventions. For women with CHD, aspirin, beta-blockers, and angiotensin-converting enzyme inhibitors should be considered. Widespread under-use of established preventive therapies has been documented in women. These interventions should be emphasized in clinical practice.
For secondary prevention of CHD in women, the American Heart Association (AHA) recommends against initiating hormone replacement therapy (HRT) based on studies that have shown no benefit and early harm. For patients with CHD already on HRT, the decision to continue or stop HRT should be based on established noncoronary benefits and risks and patient preference.
There are insufficient data to suggest that HRT should be initiated for the sole purpose of primary prevention of CHD.
Because the new AHA guidelines recommend placing significant weight on the noncardiac benefits and risks of HRT, it is important to become familiar with these noncardiac effects. It is also important to understand the evidence supporting the AHA’s decision to recommend placing relatively less weight on the cardiac effects of HRT.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613. This randomized controlled trial (HERS) of Prempro vs placebo is the largest published secondary prevention trial of HRT in women with CHD. The results showed no benefit of HRT in cardiac morbidity or mortality after 4 to 5 years.PubMedCrossRefGoogle Scholar
- 2.Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995, 273:199–208.Google Scholar
- 7.The Coronary Drug Project design and methods, and baseline results. Coronary Drug Project Research Group. Circulation 1973, 47(suppl 3):1–60.Google Scholar
- 13.Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000, 343:522–529. This randomized controlled trial (ERA) found no angiographic differences in 309 women randomized to Premarin, Prempro, or placebo.PubMedCrossRefGoogle Scholar
- 17.National Institutes of Health, National Heart, Lung, and Blood Institute. Women’s Health Initiative. URL: www.nhlbi.nih.gov/whi/hrt-en.htm; accessed December 14, 2001.Google Scholar
- 18.Mosca L, Collins P, Herrington DM, et al.: Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 104:499–503. This article includes the American Heart Association’s November 2001 guidelines regarding HRT and cardiovascular disease in women and the evidence supporting these guidelines.PubMedGoogle Scholar
- 23.Viscoli CM, Brass LM, Kernan WN, et al.: Estrogen after ischemic stroke: effect of estrogen replacement on risk of recurrent stroke and death in the Women’s Estrogen for Stroke Trial (WEST) [abstract]. Stroke 2001, 32:329.Google Scholar